Intellia Therapeutics says one dose of Nex-Z shows durable TTR reductions of at least 90% through three years
I'm PortAI, I can summarize articles.
Sept 25 (Reuters) - Intellia Therapeutics Inc:Intellia Therapeutics announces positive longer-term phase 1 data for nexiguran ziclumeran (Nex-Z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy Intellia Therapeutics Inc - one dose of Nex-Z shows durable TTR reductions of at least 90% through three years Intellia Therapeutics Inc - favorable safety data with no new drug-related events Intellia Therapeutics Inc - phase 3 Magnitude-2 trial enrollment expected by first half 2026
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments